Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Incidental but we are owners of -

Parivid [page 16-17 of the 2015 annual report]

In April 2007, we entered into an asset purchase agreement with Parivid, LLC, or Parivid, a provider of data integration and analysis services to us, and S. Raguram, the principal owner and Chief Technology Officer of Parivid. Pursuant to the purchase agreement, we acquired certain of the assets and assumed certain of the liabilities of Parivid related to the acquired assets in exchange for $2.5 million in cash paid at closing and up to $11.0 million in contingent milestone payments in a combination of cash and/or stock in the manner and on the terms and conditions set forth in the purchase agreement if certain milestones are achieved within fifteen years of the date of the purchase agreement. Between 2009 and 2011, we made cash payments to Parivid of $7.3 million and issued 91,576 shares of our common stock valued at $10.92 per share to Parivid in satisfaction of certain milestones under the purchase agreement. Under the purchase agreement, which was amended in August 2009 and July 2011, Parivid remains eligible to receive up to $4.0 million of our common stock if GLATOPA remains the sole generic COPAXONE 20 mg product on the market through the one-year anniversary of commercial launch in June 2016

http://files.shareholder.com/downloads/MNTA/2038464922x0x883876/5647EA7C-DA0C-4236-9B2D-125D1CCDEEF9/SEC-MNTA-1047469-16-10502.pdf